Trials to watch: Four biologics concluding pivotal COPD trials

The chronic obstructive pulmonary disorder (COPD) market has laid relatively dormant for the past few years until recently.

Several biologics which have been given the greenlight in asthma have not met the mark in COPD, with both GSK and AstraZeneca facing hurdles.

“We have seen this before, especially in the field of airway disease, asthma and COPD, the first round sometimes failed and then they tweaked the protocol, a slightly different patient population, or a different dose and it worked,” says Dr. Michael Segel, attending physician in pulmonology at the Sheba Hospital, Israel.